Smoking History as a Predictor of Pemetrexed Monotherapy in Patients with Non-Squamous Non-Small Cell Lung Cancer.

摘要: Background: Pemetrexed monotherapy has come to be recognized as the standard of care for second-line therapy non-squamous non-small cell lung cancer (NSCLC). Thymidylate synthase (TS) expression is a potential predictor response pemetrexed-based chemotherapy in patients with advanced NSCLC. The purpose this study was identify useful predictors pemetrexed other than TS expression. Methods: records NSCLC without driver mutations who received second or later line at Kitasato University Hospital between March 2009 and October 2015 were retrospectively reviewed, treatment outcomes evaluated. Results: In 116 NSCLC, overall rate progression-free survival (PFS) 10.3% 2.1 months, respectively. disease control PFS differed significantly among current smokers never-smokers/former light (44.9 vs. 65.8%, 1.8 4.0 respectively). Furthermore, multivariate analysis identified Eastern Cooperative Oncology Group Performance Status smoking status independent PFS. Conclusion: clinical data obtained may provide valuable basis use wild-type patients.